BLCM

Bellicum Pharmaceuticals, Inc. (BLCM) | Rumor.io

Bellicum Pharmaceuticals

BLCM

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BLCM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Nov 15

Bellicum Pharmaceuticals, Inc.'s stock, BLCM, experienced significant price gains, reaching as high as $0.19 with an 86.09% increase.
The stock's price fluctuated throughout the day, with a peak of $0.18965 and a low of $0.1875, both with substantial percentage increases.
BLCM's price movements were among the top gains, with the stock ranking as the top gainer at various points during the day.

Generated by AI

Sentiment

Of the messages about BLCM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100%
Bearish	—	—	0%	0%

Bullish· May 10

The company has a strong financial position with $21 million in cash, and a significant investor has taken a 20% equity stake.
A short squeeze is imminent, with many users believing that the shorts will be "squeezed so hard they will be begging for it" and that the stock will "send this to the moon".
The stock is likely to experience a significant price increase, with users predicting a "moonshot" and a price target of $2.00 or more.

Bearish· May 8

The author believes that Bellicum Pharmaceuticals' price will drop to $1.50 to $2.00 due to a technical chart analysis.
The company's recent price movement is seen as a "bait to screw retail", implying that the price increase was not sustainable.
The author expects the stock to drop down to 55-60 cents, citing a supposed trend of the stock performing poorly compared to other assets.

Generated by AI

Topics

Of the messages about BLCM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	50%	41.67%
Announcements	—	—	50%	58.33%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Earnings· Aug 7

Bellicum Pharmaceuticals ($BLCM) reported earnings, missing EPS loss estimates by $0.05.
The company's revenues were slightly higher than expected.
$BLCM's stock price declined after hours during the earnings conference call.

Analysts· Apr 12

Wells Fargo upgraded Bellicum Pharmaceuticals to Outperform with a price target of $23.
SunTrust Robinson Humphrey raised the price target for Bellicum Pharmaceuticals to $23.
Cantor Fitzgerald set the price target for Bellicum Pharmaceuticals at $18.

Announcements· May 9

A buyout transaction for Bellicum Pharmaceuticals ($BLCM) is expected to be announced soon, with competing bids potentially already on the table.
The value of the transaction is expected to be based on the value of the company's switch technology and its position in the biotech and pharma industry.
Analysts have recently begun covering Bellicum Pharmaceuticals, indicating increased interest in the company's prospects.

Technical Analysis· May 8

Bellicum Pharmaceuticals' ($BLCM) chart shows a descending triangle with bearish implications, with the company's major support lying at $0.6950-$0.7130.
A potential breakout is indicated on the 15-minute chart, with key resistance at $0.8650 and key support at $0.75.
The stock's MACD Histogram has turned positive, indicating an uptrend, and the company is holding above its 8-EMA on the 30-minute chart.

Generated by AI

Community

Of the messages about BLCM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	0%
Newcomers	—	—	100%	100%

Regulars· May 9

$BLCM is down 11.72% at $0.7239 with a significant increase in volume.
The stock's price may drop due to breaking above the higher Bollinger Band.
The stock is currently trading at $0.7105 with a volume of 1M, significantly higher than the average volume of 8M.

Newcomers· May 9

$BLCM is being compared to $BDRX due to similarities in their charts, with the latter experiencing a significant increase to $1.30.
$BLCM and $TRVN are among the top gainers and losers, with $BLCM being a main focus for one user.
$BLCM is identified as a beaten-down NASDAQ biotech stock with massive upside potential, making it a "hot stock to watch" according to one user.

Generated by AI

Also Discussed

Investors talking about BLCM also mention

#	Name	Attention
1	Cellectis S.A. ADRCLLS	0%0
2	BLUE - bluebird bio, Inc.	——
3	SGEN - Seagen Inc.	——
4	AFMD - Affimed N.V.	——
5	Incyte Corp.INCY	0%new
6	JNCE - Jounce Therapeutics, Inc.	——
7	Calithera Biosciences Inc.CALA	0%0
8	PRTK - Paratek Pharmaceuticals, Inc.	——
9	Novartis AG Sponsored ADRNVS	0%-0.01
10	iShares Biotechnology ETFIBB	0.01%0